SCHEMBL10193096

SCHEMBL10193096

Cc1nc(-c2ccc(-c3nc(-c4cc(-c5noc(-c6ccc(-c7noc(C)n7)cc6)n5)cc(-c5noc(-c6ccc(-c7noc(C)n7)cc6)n5)c4)no3)cc2)no1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.65
NPC1 O15118 9/20 0.59
RAB9A P51151 9/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
NR1H4 Q96RI1 4/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
MAPT P10636 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
PLK1 P53350 1/20 0.53
GAA P10253 1/20 0.51
LMNA P02545 2/20 0.51
THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2618872 0.94 L3MBTL1 (0.67) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL13167090 0.91 L3MBTL1 (0.80) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL13167094 0.89 L3MBTL1 (0.77) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL13415303 0.87 LMNA (0.67) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL13415301 0.86 L3MBTL1 (0.69) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL10192395 0.86 L3MBTL1 (0.83) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL2618505 0.84 L3MBTL1 (0.86) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL13167415 0.84 L3MBTL1 (0.86) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL16579414 0.84 L3MBTL1 (0.86) L3MBTL1NPC1RAB9ANFKB1NFKB2
SCHEMBL2618901 0.83 LMNA (0.66) L3MBTL1NPC1RAB9ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9316843-B2 Stereoscopic image recognition apparatus FUJIFILM CORPORATION (JP) 2016-04-19 US disclosed
US-20150080582-A1 OPTICAL FILM, RETARDATION PLATE, ELLIPTICA POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE AND COMPOUND FUJIFILM CORPORATION (JP) 2015-03-19 US disclosed
US-8981108-B2 Optical film, retardation plate, elliptica polarizing plate, liquid crystal display device and compound FUJIFILM CORPORATION (JP) 2015-03-17 US disclosed
US-8842243-B2 IPS or FFS-mode liquid-crystal display device FUJIFILM CORPORATION (JP) 2014-09-23 US disclosed
US-20120194767-A1 IPS OR FFS-MODE LIQUID-CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2012-08-02 US disclosed
US-20120099033-A1 STEREOSCOPIC IMAGE RECOGNITION APPARATUS FUJIFILM CORPORATION (JP) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080582-A1 OPTICAL FILM, RETARDATION PLATE, ELLIPTICA POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE AND COMPOUND PYM1, CCND2, CCNB2 L3MBTL1 101/4885NPC1 4454/4885RAB9A 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.